The alterations targeted included two patients with glioblastoma that had MET amplifications, one patient with melanoma with CDK4 amplification, a breast cancer patient with an FGFR1 amplification, a patient with colorectal cancer with an ALK mutation, a colorectal cancer patient with a PIK3R1 mutation, and a leiomyosarcoma patient with a PTEN mutation. The gene discussed is ALK; the disease is melanoma.